Adjuvant chemotherapy for breast cancer, Volume 20
U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, Office of Medical Applications of Research, 1985 - Breast - 5 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
ablation or tamoxifen Adjuvant Chemo Applications of Research axillary lymph nodes benefit of tamoxifen Biostatistics breast cancer Cancer Institute National clinical investigation Consensus Development Conference cytotoxic chemotherapy Decisions regarding adjuvant disease-free survival dose effects of adjuvant Harvard Medical School Health Bethesda histologically negative axillary hormonal therapy hormone receptor levels increase in survival Institute National Institutes Institutes of Health leukemia M.D. Associate Clinical M.D. Chairman M.D. Director Maryland Medical Applications Medical Oncology National Cancer Institute negative axillary lymph negative estrogen receptors negative hormone receptors negative nodes nodes and positive Nodes Receive Adjuvant number Office of Medical optimal duration ovarian ablation overall survival Pathology patients with negative patients with positive positive axillary lymph positive hormone receptor positive nodes postmenopausal patients postmenopausal women Premenopausal Adjuvant premenopausal patients premenopausal women Professor of Medicine Radiation Therapy regimens Research National Institutes side effects therapy of breast tumor University of Pennsylvania women with histologically women with negative